Arcus Biosciences (RCUS) Amortizatization of Intangibles (2017 - 2026)
Arcus Biosciences (RCUS) recorded quarterly Amortizatization of Intangibles of $3.0 million in Q1 2026, down 62.5% quarter-over-quarter from $8.0 million in Q4 2025, and down 25.0% on a YoY basis from $4.0 million in Q1 2025.
Arcus Biosciences (RCUS) Amortizatization of Intangibles (2017 - 2026) Analysis & Trends
Arcus Biosciences' Amortizatization of Intangibles history runs 10 years deep, the most recent figure standing at $3.0 million for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 25.0% year-over-year to $3.0 million; the TTM figure through Mar 2026 stood at $12.0 million (up 33.33% YoY), while the FY2025 annual figure was $13.0 million, up 85.71% from the prior year.
- Amortizatization of Intangibles was $3.0 million for Q1 2026 at Arcus Biosciences, down from $8.0 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $11.0 million in Q2 2024 to a low of -$12.0 million in Q4 2024.
- Historically, Amortizatization of Intangibles has averaged $2.9 million across 5 years, with a median of $3.0 million in 2026.
- The sharpest annual moves came in 2022 and 2024: Amortizatization of Intangibles jumped 762.25% in 2022, then sank 300.0% in 2024.
- A 5-year view of Amortizatization of Intangibles shows it stood at $2.0 million in 2022, then soared by 200.0% to $6.0 million in 2023, then tumbled by 300.0% to -$12.0 million in 2024, then soared by 166.67% to $8.0 million in 2025, then tumbled by 62.5% to $3.0 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $3.0 million (Q1 2026), $8.0 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 13,267.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcus Biosciences | 3.05 Bn | 2.23 Bn | - | 3.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.00 Mn |
| Mar 31, 2026 | 3.00 Mn |
| Dec 31, 2025 | 8.00 Mn |
| Dec 31, 2025 | 8.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.00 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Jun 30, 2025 | -1.00 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Mar 31, 2025 | 4.00 Mn |
| Dec 31, 2024 | -12.00 Mn |
| Dec 31, 2024 | -12.00 Mn |
| Sep 30, 2024 | 6.00 Mn |
| Sep 30, 2024 | 6.00 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Jun 30, 2024 | 11.00 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Mar 31, 2024 | 2.00 Mn |
| Dec 31, 2023 | 6.00 Mn |
| Dec 31, 2023 | 6.00 Mn |